JMP Securities Reiterates Market Outperform on DocuSign, Maintains $84 Price Target
JMP Securities analyst Joe Goodwin reiterates DocuSign (NASDAQ:DOCU) with a Market Outperform and maintains $84 price target.
EF Hutton Reiterates Buy on KLX Energy Services Hldgs, Maintains $30 Price Target
EF Hutton analyst Ignacio Bernaldez reiterates KLX Energy Services Hldgs (NASDAQ:KLXE) with a Buy and maintains $30 price target.
EF Hutton Reiterates Buy on Mind Medicine, Maintains $21 Price Target
EF Hutton analyst Elemer Piros reiterates Mind Medicine (NASDAQ:MNMD) with a Buy and maintains $21 price target.
Needham Reiterates Buy on Taiwan Semiconductor, Maintains $110 Price Target
Needham analyst Charles Shi reiterates Taiwan Semiconductor (NYSE:TSM) with a Buy and maintains $110 price target.
Needham Reiterates Buy on HashiCorp, Maintains $39 Price Target
Needham analyst Alex Henderson reiterates HashiCorp (NASDAQ:HCP) with a Buy and maintains $39 price target.
Needham Reiterates Buy on Stratasys, Maintains $15 Price Target
Needham analyst James Ricchiuti reiterates Stratasys (NASDAQ:SSYS) with a Buy and maintains $15 price target.
Needham Reiterates Buy on AgileThought, Maintains $7 Price Target
Needham analyst Mayank Tandon reiterates AgileThought (NASDAQ:AGIL) with a Buy and maintains $7 price target.
HC Wainwright & Co. Reiterates Neutral on Akebia Therapeutics, Maintains $1.25 Price Target
HC Wainwright & Co. analyst Ed Arce reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Neutral and maintains $1.25 price target.
HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:LIFE) with a Buy and maintains $35 price target.
HC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $15 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:ALDX) with a Buy and maintains $15 price target.